Accium BioSciences

About:

Accium BioSciences is a Developer of an ultrasensitive detection platform.

Top Investors: WRF Capital

Description:

Developer of an ultrasensitive detection platform designed to overcome challenges faced in clinical development of novel drugs. The company's ultrasensitive detection platform investigates pharmacologic and pharmacodynamic endpoints of Merck's Temodar® in glioblastoma multiforme (GBM) patients, providing 14C-methylation measurements of tumor DNA after 14C-Temodar® administration. The purpose of the study is to identify pharmacologic or pharmacodynamic endpoints that may be predictive of response to therapy in individual patients, enabling clinicians to involve therapeutic response prediction and resistance to treatment.

Total Funding Amount:

$3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Seattle, Washington, United States

Founded Date:

2004-05-01

Contact Email:

info(AT)acciumbio.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2006-01-09

IPO Status:

Private

Industries: